RNA therapeutics have advanced significantly over the past decade, particularly in the production and application of small interference (si)RNA and antisense oligonucleotides (ASOs). Innovative manufacturing solutions are necessary to overcome limitations in current solid-phase oligonucleotide synthesis (SPOS) technology, which faces challenges such as quality compromise and environmental sustainability. The future of RNA manufacturing is shifting towards enzyme-enabled processes that promise scalability, better yields, and reduced hazardous waste, addressing regulatory and market demands.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.